Quantum BioPharma Raises CAD 3.75M in Debenture Offering, Settles CAD 1.12M Debt
Quantum BioPharma issued 3,750 debenture units to raise CAD 3.75 million in its initial private placement tranche, including a CAD 300,000 subscription from a director under MI 61-101 exemptions. It also settled CAD 1.12 million of debt by issuing 370,457 Class B shares to creditors and insiders.
1. Initial Tranche Closing
Quantum BioPharma closed the first tranche of its private placement on March 20, 2026, issuing 3,750 Debenture Units and raising CAD 3.75 million to support business development and working capital needs.
2. Director Participation and Exemptions
One director subscribed for CAD 300,000 of Debenture Units, constituting a related party transaction under MI 61-101, with the company relying on valuation and minority approval exemptions since the transaction value did not exceed 25% of market capitalization.
3. Debt Settlement
The company settled approximately CAD 1.12 million of outstanding debt by issuing 370,457 Class B subordinate voting shares to arm’s length creditors and insiders, also relying on MI 61-101 exemptions to expedite completion.
4. Use of Proceeds and Capital Structure
Proceeds from the placement will fund ongoing R&D and general operations, while the debt settlement and new share issuance modestly expand the outstanding share count and strengthen the balance sheet.